Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal
- 16 August 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (9) , 777-781
Abstract
A recent study has demonstrated an increased risk of neurodevelopmental disorders, including autism spectrum disorder, in individuals exposed to either valproate or topiramate monotherapy. Regulatory bodies have initiated a review to reassess the safety of topiramate exposure during pregnancy. These novel findings raise concerns regarding the recommendation of antiseizure medications in women of childbearing potential. This manuscript highlights current research defining concerns specific to the use of valproate and topiramate in women of childbearing potential. This manuscript summarizes recent findings regarding the safety of valproate and topiramate when compared to alternative therapies for the preventative treatment of migraine in women of childbearing potential. The studies included in this review were selected following a comprehensive literature review of multiple relevant databases. All studies that were published within the past 15 years were considered for inclusion. The use of valproate and topiramate in women of childbearing potential should be highly discouraged. Our recommendations include a review of current prescribing guidelines, further public education regarding the neurodevelopmental and congenital risks associated with the use of valproate and topiramate, and an appeal for further research defining the safety of alternative medications for migraine prevention when intrauterine exposure is possible.Keywords
This publication has 29 references indexed in Scilit:
- Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomesBMC Medicine, 2017
- A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experienceThe Journal of Headache and Pain, 2015
- Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta‐analysisClinical Pharmacology & Therapeutics, 2015
- The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical programThe Journal of Headache and Pain, 2013
- OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPTThe Journal of Headache and Pain, 2013
- Italian guidelines for primary headaches: 2012 revised versionThe Journal of Headache and Pain, 2012
- Valproic Acid Monotherapy in Pregnancy and Major Congenital MalformationsNew England Journal of Medicine, 2010
- Valproic acid in pregnancy: How much are we endangering the embryo and fetus?Reproductive Toxicology, 2009
- Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohortsEpilepsy Research, 2008
- Migraine prevalence, disease burden, and the need for preventive therapyNeurology, 2007